Cargando…

Tivozanib for hepatocellular carcinoma: not likely a new option

Detalles Bibliográficos
Autores principales:	Estrade, Florian, Le Du, Fanny, Crouzet, Laurence, Bourien, Héloïse, Muzellec, Léa, Edeline, Julien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723626/ https://www.ncbi.nlm.nih.gov/pubmed/33313082 http://dx.doi.org/10.21037/atm-20-3389

Ejemplares similares

Patients’ Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life
por: Muzellec, Léa, et al.
Publicado: (2021)

ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma
por: Lescure, Céline, et al.
Publicado: (2021)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012)

Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013)

Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
por: Westerman, Mary E., et al.
Publicado: (2020)

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
por: Rodenburg, RJ, et al.
Publicado: (2019)

A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
por: Fountzilas, Christos, et al.
Publicado: (2020)

Lenvatinib in elderly hepatocellular carcinoma patients, a new therapeutic option in first line
por: Roth, Gael S., et al.
Publicado: (2020)

Development of multiplex digital PCR assays for the detection of PIK3CA mutations in the plasma of metastatic breast cancer patients
por: Corné, Julien, et al.
Publicado: (2021)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
por: Yalcin, Suayib, et al.
Publicado: (2019)

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma
por: Sakellakis, Minas, et al.
Publicado: (2023)

Milestones for development of tivozanib for kidney cancer therapy
por: Crescentini, Robert, et al.
Publicado: (2012)

Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature
por: Caquelin, Laura, et al.
Publicado: (2022)

Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?
por: Bourien, Héloïse, et al.
Publicado: (2023)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Tivozanib: a novel VGFR inhibitor for kidney cancer
por: Boyle, Helen
Publicado: (2013)

Hepatocellular carcinoma in elderly patients: challenges and solutions
por: Brunot, Angélique, et al.
Publicado: (2016)

Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
por: Catanese, Silvia, et al.
Publicado: (2020)

Eph receptor B2 (EPHB2) regulates cancer stem cell-like properties in hepatocellular carcinoma
por: Lim, Jhin Jieh, et al.
Publicado: (2022)

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012)

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model
por: Alanazi, Wael A., et al.
Publicado: (2023)

The Potential Implication of the Autonomic Nervous System in Hepatocellular Carcinoma
por: Parent, Romain, et al.
Publicado: (2019)

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

A new era for hepatocellular carcinoma
por: Memeo, Riccardo, et al.
Publicado: (2023)

Time to stop using hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma?—the SCOOP-2 trial experience
por: Peck-Radosavljevic, Markus, et al.
Publicado: (2020)

Doxorubicin for the treatment of hepatocellular carcinoma: GAME OVER!
por: Guiu, Boris, et al.
Publicado: (2020)

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
por: Molina, Ana M., et al.
Publicado: (2018)

Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice
por: Celsa, Ciro, et al.
Publicado: (2023)

Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner
por: Campani, Claudia, et al.
Publicado: (2020)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

In silico trials of combination immuno-radiation for unresectable hepatocellular carcinoma
por: Mendiratta-Lala, Mishal, et al.
Publicado: (2023)

Chemoembolization combined with radiofrequency ablation is the best option for the local treatment of early hepatocellular carcinoma?
por: Kim, Hyo-Cheol
Publicado: (2023)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Lipids link immune suppression to effective immunotherapy in steatotic hepatocellular carcinoma
por: Li, Bing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sm39a44k82k6mn9dcqd489g73n